Suppr超能文献

迈向脑源性神经营养因子的控释——载蛋白脂质植入物的制造策略及脑内生物相容性评估

Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain.

作者信息

Koennings S, Sapin A, Blunk T, Menei P, Goepferich A

机构信息

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstr, 31, 93040 Regensburg, Germany.

出版信息

J Control Release. 2007 Jun 4;119(2):163-72. doi: 10.1016/j.jconrel.2007.02.005. Epub 2007 Feb 20.

Abstract

It was the aim of this study to establish triglyceride matrices as potential carriers for long-term release of brain-derived neurotrophic factor (BDNF), a potential therapeutic for Huntington's disease. First, four different manufacturing strategies were investigated with lysozyme as a model substance: either lyophilized protein was mixed with lipid powder, or suspended in organic solution thereof (s/o). Or else, an aqueous protein solution was dispersed by w/o emulsion in organic lipid solution. Alternatively, a PEG co-lyophilization was performed prior to dispersing solid protein microparticles in organic lipid solution. After removal of the solvent(s), the resulting powder formulations were compressed at 250 N to form mini-cylinders of 2 mm diameter, 2.2 mm height and 7 mg weight. Protein integrity after formulation and release was evaluated from an enzyme activity assay and SDS-PAGE. Confocal microscopy revealed that the resulting distribution of FITC-lysozyme within the matrices depended strongly on the manufacturing method, which had an important impact on matrix performance: matrices with a very fine and homogeneous protein distribution (PEG co-lyophilization) continually released protein for 2 months. The other methods did not guarantee a homogeneous distribution and either failed in sustaining release for more than 1 week (powder mixture), completely liberating the loading (s/o dispersion) or preserving protein activity during manufacturing (w/o emulsion, formation of aggregates and 25% activity loss). Based on these results, miniature-sized implants of 1 mm diameter, 0.8 mm height and 1 mg weight were successfully loaded by the PEG co-lyophilization method with 2% BDNF and 2% PEG. Release studies in phosphate buffer pH 7.4 at 4 and 37 degrees C revealed a controlled release of either 20 or 60% intact protein over one month as determined by ELISA. SDS-PAGE detected only minor aggregates in the matrix during release at higher temperature. In vivo evaluation of lipid cylinders in the striatum of rat brains revealed a biocompatibility comparable to silicone reference cylinders.

摘要

本研究的目的是建立甘油三酯基质,作为脑源性神经营养因子(BDNF,一种治疗亨廷顿舞蹈症的潜在药物)长期释放的潜在载体。首先,以溶菌酶为模型物质研究了四种不同的制备策略:将冻干蛋白与脂质粉末混合,或将其悬浮于脂质的有机溶液中(s/o)。或者,将蛋白质水溶液通过油包水乳液分散于有机脂质溶液中。另外,在将固体蛋白质微粒分散于有机脂质溶液之前进行聚乙二醇共冻干。去除溶剂后,将所得粉末制剂在250 N压力下压制成直径2 mm、高2.2 mm、重7 mg的微型圆柱体。通过酶活性测定和SDS-PAGE评估制剂和释放后的蛋白质完整性。共聚焦显微镜显示,所得异硫氰酸荧光素标记的溶菌酶在基质中的分布很大程度上取决于制备方法,这对基质性能有重要影响:蛋白质分布非常精细且均匀的基质(聚乙二醇共冻干)持续释放蛋白质达2个月。其他方法不能保证均匀分布,要么在1周以上的时间内无法维持释放(粉末混合物),要么完全释放所载物质(s/o分散体),要么在制备过程中无法保持蛋白质活性(油包水乳液,形成聚集体且活性损失25%)。基于这些结果,采用聚乙二醇共冻干方法成功制备了直径1 mm、高0.8 mm、重1 mg的微型植入物,其中负载了2%的BDNF和2%的聚乙二醇。在4℃和37℃下于pH 7.4的磷酸盐缓冲液中进行的释放研究显示,通过酶联免疫吸附测定法测定,在1个月内有20%或60%的完整蛋白质实现了控释。SDS-PAGE检测发现在较高温度下释放过程中基质中只有少量聚集体。对大鼠脑纹状体中脂质圆柱体的体内评估显示其生物相容性与硅酮对照圆柱体相当。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验